50 articles, transcripts, and reports
Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today. Total revenue increased 3% year-over-year to $2.5 billion. Net income attributable to…
Biogen Inc. (NASDAQ: BIIB) reported its third quarter 2024 earnings results today. Total revenue decreased 3% year-over-year to $2.46 billion. Revenues were down 3% on…
Biogen Inc. (NASDAQ: BIIB) reported its second quarter 2024 earnings results today. Total revenue of $2.5 billion was flat at actual currency and up 1%…
Biogen Inc. (NASDAQ: BIIB) reported third quarter 2023 earnings results today. Total revenue rose 1% year-over-year to $2.53 billion. Revenues grew 3% in constant currency.…
Biogen Inc (NASDAQ:BIIB) Q1 2023 Earnings Call dated Apr. 25, 2023. Corporate Participants: Chuck Triano — Head of Investor Relations Christopher Viehbacher — President and Chief Executive Officer Priya…
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the first quarter of 2023. Total revenue declined 3%…
Biogen, Inc. (NASDAQ: BIIB) Q4 2022 earnings call dated Feb. 15, 2023 Corporate Participants: Michael Hencke — Head of Investor Relations Christopher A. Viehbacher — President and Chief Executive…
Biogen Inc. (NASDAQ: BIIB) reported fourth quarter 2022 earnings results today. Total revenue fell 7% year-over-year to $2.54 billion. Net income attributable to Biogen Inc.…
Biogen Inc. (NASDAQ: BIIB) Q3 2022 earnings call dated Oct. 25, 2022 Corporate Participants: Mike Hencke — Head, Investor Relations Michel Vounatsos — Chief Executive Officer Priya Singhal — Head, Global…
Pharma giant Biogen Inc. (NASDAQ: BIIB) on Tuesday announced financial results for the third quarter of 2022, reporting a double-digit drop in revenues and adjusted…
